Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 8/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 9/20 | 0.35 |
| ▸ | MMP13 | P45452 | 9/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 2/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22590204 | 0.91 | SCN8A (0.41) | MMP9SCN8ANR1I2SCN1ASCN1B | |
| SCHEMBL19613710 | 0.90 | ACLY (0.38) | MMP9ACLYL3MBTL1MMP1MMP13 | |
| SCHEMBL19631690 | 0.88 | SCN8A (0.35) | MMP9SCN8ANR1I2SCN1ASCN1B | |
| SCHEMBL19631521 | 0.87 | ACLY (0.36) | MMP9ACLYL3MBTL1MMP1MMP13 | |
| SCHEMBL19613447 | 0.82 | ACLY (0.44) | MMP9SCN8ANR1I2SCN1ASCN1B | |
| SCHEMBL19614139 | 0.81 | SCN8A (0.40) | MMP9SCN8ASCN1AMMP1MMP13 | |
| SCHEMBL19614141 | 0.81 | SCN8A (0.40) | MMP9SCN8ASCN1AMMP1MMP13 | |
| SCHEMBL19613502 | 0.81 | ACLY (0.37) | MMP9SCN8ANR1I2SCN1ASCN1B | |
| SCHEMBL21789155 | 0.81 | CNR2 (0.41) | MMP9ACLYMMP1MMP13CNR1 | |
| SCHEMBL29447385 | 0.79 | ALDH1A1 (0.40) | MMP9SCN8ASCN1AMMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-05-26 | — | — | US | disclosed |
| US-20190194184-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2019-06-27 | — | — | US | disclosed |
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2019-04-02 | — | — | US | disclosed |
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | MMP9 2419/4885SCN8A 14/4885NR1I2 1297/4885 |
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | MMP9 2419/4885SCN8A 14/4885NR1I2 1297/4885 |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | MMP9 2594/4885SCN8A 10/4885NR1I2 1617/4885 |
| US-20190194184-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | MMP9 2594/4885SCN8A 10/4885NR1I2 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.